Pharmacogenomics in Alzheimer's disease

Methods in Pharmacology and Toxicology

Volumn , Issue , 2008, Pages 317-368

  Cacabelos, Ramón ^a,b  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

ACE; Alzheimer's disease; anxiety; APOE; cholinesterase inhibitors; cognition; combination therapy; CYP2D6; genetics; genomics; pharmacogenetics; pharmacogenomics

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; AMYLOID; APOLIPOPROTEIN E4; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; BETA SECRETASE INHIBITOR; CASPASE INHIBITOR; CHOLINESTERASE INHIBITOR; CITICOLINE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2D6; DONEPEZIL; DOPAMINE UPTAKE INHIBITOR; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HISTAMINE H3 RECEPTOR ANTAGONIST; MEMANTINE; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICERGOLINE; NICOTINIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIRACETAM; PSYCHOTROPIC AGENT; RIVASTIGMINE; SEROTONIN AGONIST; TACRINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; BEHAVIOR; BRAIN ATROPHY; BRAIN BLOOD VESSEL; BRAIN ELECTROPHYSIOLOGY; CAUCASIAN; COGNITION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEMENTIA; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; FUNCTIONAL GENOMICS; GENE INTERACTION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEMODYNAMICS; HETEROZYGOTE; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; LIPID METABOLISM; MOOD; NERVE CELL NECROSIS; ONSET AGE; PATHOGENESIS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; STRUCTURAL GENOMICS;

EID: 78649395252     PISSN: 15572153     EISSN: 19406053     Source Type: Book Series    
DOI: 10.1007/978-1-59745-439-1_16     Document Type: Review

References (115)

1. Cacabelos R, Alvarez XA, Lombardi V et al. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000;36:415-99.
2. Giacobini E. Cholinesterases in the human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In: Giacobini E, Pepeu G (ed). The brain cholinergic system in health and disease. Informa Healthcare, Oxford, 2006 pp 235-64.
3. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer's disease. Health Technl Assess 2006;10:1-176.
4. Cacabelos R, Fernández-Novoa L, Lombardi V, Kubota Y, Takeda M. Molecular genetics of Alzheimer's disease and aging. Meth Find Exper Clin Pharmacol 2005;27 (Suppl. A):1-573.
5. Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2003;4:597-621.
6. Cacabelos R, Alvarez A, Fernández-Novoa L, Lombardi VRM. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol Scand 2000;176(Suppl.):12-9.
7. Cacabelos R. Pharmacogenomics in Alzheimer's disease. Min Rev Med Chem 2002;2:59-84.
8. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002;34:357-79.
9. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Rev Genet 2004;5:645-56.
10. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp Opin Pharmacother 2005;6:1967-87.
11. Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health 2005;1:303-48.
12. Cacabelos R, Takeda M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future 2006;31(Suppl B):5-146.
13. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nature Rev Genet 2003;4:937-47.
14. Austin CP. The impact of the completed human genome sequence on the development of novel therapeutics for human disease. Annu Rev Med 2004;55:1-13.
15. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002;3:67-99.
16. Doshi JA, Shaffer T, Briesacher BA. National estimates of medication use in nursing homes: findings from 1997 Medicare current beneficiary survey and the 1996 medical expenditure survey. J Am Geriatr Soc 2005;53:438-43.
17. Fialová D, Topinková E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005;293:1348-58.
18. Simon SR, Chan KA, Soumerai SB, et al. Potentially inappropriate medication use by elderly persons in U.S. health maintenance organizations, 2000-2001. J Am Geriatr Soc 2005;53:227-32.
19. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 2006;7:223-45.
20. http://www.ncbi.nlm.nih.gov/OMIM
21. www.molgen.ua.ac.be/ADMutations/
22. Cacabelos R, Fernández-Novoa L, Corzo L, Pichel V, Lombardi V, Kubota Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth Find Exper Clin Pharmacol 2004;26:421-44. (Pubitemid 39079109)
23. Cacabelos R, Kubota Y, Isaza C, et al. Functional genomics and pharmacogenetics in Alzheimer's disease. In: Recent progress in Alzheimer's and Parkinson's disease. Hanin I, Cacabelos R, Fisher A. (eds) Taylor & Francis, London, 2005 pp 89-102.
24. www.mitomap.org/
25. Hunter DJ. Gene-environment interactions in human diseases. Nature Rev Genet 2005;6:287-98.
26. Teter B, Finch CE. Caliban's heritance and the genetics of neuronal aging. Trends Neurosci 2004;27:627-32.
27. Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. Nature Rev Neurosci 2005;6:108-18.
28. Suh Y-H, Checler F. Amyloid precursor protein, presenilins, and a-synuclein: Molecular pahogenesis and pharmacological applications in Alzheimer's disease. Phamacol Rev 2002;54:469-525.
29. Sharp AJ, Cheng Z, Eichler EE. Structural variation of human genome. Annu Rev Genomics Hum Genet 2006;7:407-42.
30. Crawford DC, Akey DT, Nickerson DA. The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet 2005;6:287-312.
31. Cacabelos R, Fernández-Novoa L, Lombardi V, Takeda M. Genetic variation and pharmacogenomics in Alzheimer disease. Psychiat Neurol Jap 2003;105:47-67.
32. Gregersen N, Bross P, Vang S, Christensen JH. Protein misfolding and human disease. Annu Rev Genomics Hum Genet 2006;7:103-24.
33. Cacabelos R, Fernández-Novoa L, Lombardi V, Corzo L, Pichel V, Kubota Y. Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications. Neurol Res 2003;25:567-80.
34. Cacabelos R, Fernández-Novoa L, Corzo L, et al. Phenotypic profiles and functional genomics in dementia with a vascular component. Neurol Res 2004;26:459-80.
35. Cacabelos R, Lombardi V, Fernández-Novoa L, et al. A functional genomics approach to the analysis of biological markers in Alzheimer disease. In: Molecular neurobiology of Alzheimer disease and related disorders. Takeda M, Tanaka T, Cacabelos R (eds). Karger, Basel, 2004 pp 236-85.
36. Cacabelos R. Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics 2004;5:1049-105.
37. Van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Aβ1-40 and Aβ1- 42) and the risk of dementia: prospective case-cohort study. Lancet Neurol 2006;5:655-60.
38. Cacabelos R. The histamine-cytokine network in Alzheimer disease: Etiopathogenic and pharmacogenomic implications. In: Mapping Progress of Alzheimer's and Parkinson's diseases. Advances in behavioral biology, vol. 51. Mizuno Y, Fisher A, Hanin I (eds). Pergamon Press, New York, 2002 pp 59-64.
39. Fernández-Novoa L, Cacabelos R. Histamine function in brain disorders. Behav Brain Res2001;124:213-33.
40. Hogan DB, Goldlist B, Naglie G, Patterson C. Comparison studies of cholinesterase inhibitors for Alzheimer''s disease. Lancet Neurol 2004;3:622-8.
41. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteux JM. Impact of genomics on drug discovery and clinical medicine. Q J Med 2000;93:391-423.
42. Verrils NM. Clinical proteomics: present and future prospects. Clin Biochem Rev 2006;27:99-116.
43. Meyer UA. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nature Rev Genet 2004;5:669-76.
44. Cacabelos R, Fernández-Novoa L, Pichel V, Lombardi V, Kubota Y, Takeda M. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In: Molecular neurobiology of Alzheimer disease and related disorders. Takeda M, Tanaka T, Cacabelos R (eds). Karger, Basel, 2004 pp 94-107.
45. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
46. Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 2001;1:3-10.
47. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931-45.
48. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 2005;293:596-608. (Pubitemid 40171242)
49. Tribut O, Lessard Y, Reymann JM, Allain H, Bentue-Ferrer D. Pharmacogenomics. Med Sci Monit 2002;8:152-63.
50. Saito S, Ishida A, Sekine A, et al. Catalog of 680 variants among eight cytochrome P450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003;48:249-70.
51. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nature Rev Drug Discov 2006;5:956-70.
52. Wooding SP, Watkins WS, Bamshad MJ, et al. DNA sequence variations in a 3.7-kb noncoding sequence 5-prime of the CYP1A2 gene: implications for human population history and natural selection. Am J Hum Genet 2002;71:528-42.
53. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003;35:99-106.
54. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9;CYP2C19;CYP2D6;CYP1A1;NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303-12.
55. Xie HG, Prasad HG, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic ditribution and functional significance. Adv Drug Deliv Rev 2002;54:1257-70.
56. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharm Toxicol 2001;41:815-50.
57. Isaza CA, Henao J, López AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth Find Exp Clin Pharmacol 2000;22:695-705.
58. Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31:421-31.
59. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9, and CYP2A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619:243-53.
60. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000;347:321-37.
61. Hedlund E, Gustafsson JA, Warner M. Cytochrome P450 in the brain: a review. Curr Drug Metabol 2001;2:245-63.
62. www.icgeb.org/
63. www.imm.ki.se/CYPalleles/cyp2d6.htm
64. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
65. Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003;17:947-63.
66. Griese E-U, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
67. Bernal ML, Sinues B, Johansson I, et al. Ten percent of north Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 1999;9:657-60.
68. Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenicrelated effects of multifactorial treatments on cognition, anxiety, and depression. Meth Find Exper Clin Pharmacol 2007;29(Suppl. B):1-91.
69. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006;11:126-35.
70. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger. Elucidation of the genetic basis of the common intermediate metabolizer phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000;10:577-81.
71. Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest 2006;66:129-36.
72. Yamada H, Dahl ML, Viitanen M, Winblad B, Sjoqvist F, Lannfelt L. No association between familial Alzheimer disease and cytochrome P450 polymorphisms. Alzheimer Dis Assoc Disord 1998;12:204-7.
73. Chen X, Xia Y, Alford M, et al. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer''s disease. Ann Neurol 1995;38 :653-8.
74. Cervilla JA, Russ C, Holmes C, et al. CYP2D6 polymorphisms in Alzheimer's disease, with and without extrapyramidal signs, showing no apolipoprotein E epsilon 4 effect modification. Biol Psychiatry 1999;45:426-9.
75. Atkinson A, Singleton AB, Steward A, et al. CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy bodies or Alzheimer's disease. Pharmacogenetics 1999;9:31-5.
76. Nicholl DJ, Bennett P, Hiller L, et al. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 1999;53:1415-21.
77. Woo SI, Kim JW, Seo HG, et al. CYP2D64 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. Psychiatry Clin Neurosci 2001;55 :373-7.
78. Furuno T, Kawanishi C, Iseki E, et al. No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies. Psychiatry Clin Neurosci 2001;55:89-92.
79. Scordo MG, Dahl ML, Spina E, Cordici F, Arena MG. No association between CYP2D6 polymorphisms and Alzheimer's disease in an Italian population. Pharmacol Res 2006;53:162-5.
80. Cacabelos R. Pleiotropic effects of APOE in dementia: influence on functional genomics and pharmacogenetics. In: Advances in Alzheimer's and Parkinson's disease. Insights, progress, and perspectives. Fisher A, Memo M, Storchi F, Hanin I (eds), Springer, Secaucus, NJ, 2007 pp 355-367.
81. Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol 2006;62:721-6.
82. Egger SS, Bachmann A, Hubmann N, Schlienger RG, Krähenbudie;hl S. Prevalence of potentially inappropriate medication use in elderly patients. Comparison between general medicine and geriatric wards. Drugs Aging 2006;23:823-37.
83. Schuetz EG, Relling MV, Kishi S, et al. PharGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev 2004;56:159.
84. Poirier J, Delisle M-C, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:12260.4.
85. Poirier J. Apolipoprotein E4; cholinergic integrity and the pharmacogenetics of Alzheimerfs disease. J Psychiat Neurosci 1999;24:147.53.
86. Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 2001;12:22.32.
87. Sjogren M, Hesse C, Basun H, et al. Tacrine and rate of progression in Alzheimerfs disease. relation to ApoE allele genotype. J Neural Transm 2001;108:451.8.
88. Borroni B, Colciaghi F, Pastorino L, et al. ApoE genotype influences the biological effects of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol 2002;12:195.200.
89. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimerfs disease. Dement Geriatr Cogn Disord 2001;2:69.77.
90. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261.2268.
91. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimerfs disease. Pharmacogenomics 2006;6:246.54.
92. MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimerfs disease. Int J Geriatr Psychiatry 1998;13:625.30.
93. Rigaud AS, Traykov L, Caputo L, et al. The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimerfs disease. Eur J Neurol 2000;7 :255.8.
94. Rigaud AS, Traykov L, Latour F, et al. Presence of absence of least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimerfs disease. Pharmacogenetics 2002;12:415.20.
95. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379.88.
96. Bizzarro A, Marra C, Acciarri A, et al. Apolipoprotein E epsilon-4 allele differentiates the clinical response to donepezil in Alzheimerfs disease. Dement Geriatr Cogn Disord 2005;20:254.61.
97. Alvarez XA, Mouzo R, Pichel V, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimerfs disease patients. Effects on cognitive performance, brain bioelectrical activity, and cerebral perfusion. Meth Find Exp Clin Pharmacol 1999;21:633.44.
98. Alvarez XA, Pichel V, Perez PA, et al. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Meth Find Exp Clin Pharmacol 2000;22:585.94.
99. Saunders AM, Trowers MK, Shimkets RA, et al. The role of apolipoprotein E in Alzheimerfs disease: pharmacogenomic target selection. Biochem Biophys Acta 2000;1502:85.94.
100. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006;98:1123.33.
101. Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001;276:47863.8.
102. Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005;21:733.40.
103. Eckman EA, Adams SK, Troendle FJ, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 2006;281:30471-8.
104. Hemming ML, Selkoe DJ. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005;280:37644-50.
105. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006;98:887-96.
106. Baghai TC, Binder EB, Schule C, et al. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 2006;11:1003-15.
107. McLachlan CS, Yi Xing Soh C. Differences in anxiety-related behaviour between apolipoprotein E-deficient C57BL/6 and wild type C57BL/6 mice. Physiol Res 2005;54 :701-4.
108. Nebes RD, Vora IJ, Meltzer CC, et al. Relationship of deep white matter hyperintensities and apolipoprotein E genotype to depressive symptoms in older adults without clinical depression. Am J Psychiatry 2001;158:878-84.
109. Naismith S, Hickie I, Ward PB, et al. Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression. Am J Psychiatry 2002;159:2096-8.
110. O'Brien JT, Lloyd A, McKeith I, Gholkar A, Ferrier N. A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 2004;161:2081-90.
111. Hickie I, Naismith S, Ward PB, et al. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. Br J Psychiatry 2005;186:197-202.
112. Kim JM, Stewart R, Shin IS, Yoon JS. Vascular/risk and late-life depression in a Korean community population. Br J Psychiatry 2004;185:102-7.
113. Philips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nature Rev Drug Discovery 2005;4:500-9.
114. Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 2006;22:483-94.
115. Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nature Genet 2005;37:671-81.